🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Tianjin
Clinical trial register · China

Clinical Trials in Tianjin, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Tianjin 170 Beijing 4 Chengdu 4 Shijiazhuang 3 Fuzhou 2
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Institute of Hematology & Blood Diseases Hospital, China203 Tianjin Medical University Cancer Institute and Hospital170 Tianjin Medical University Second Hospital25 Tianjin Medical University25 Tianjin Medical University General Hospital17 Clear sponsor filter
Site location
Tianjin170 Beijing4 Chengdu4 Shijiazhuang3 Fuzhou2
All 32 locations
Target enrolment
to

Trials with a site in Tianjin

170 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Study on Sequential Cryoablation, Relaforp Alpha, and Chemotherapy for Bile Duct Tumors
NCT07726446Biliary Tract Cancer (BTC)
Tianjin Medical University Cancer Institute and Hospital
Phase 2
30
Tianjin
2026-10
Not yet open
Albumin-bound Paclitaxel (Ⅱ)-Combined Regimens for Pancreatic Cancer
NCT07828756Pancreatic Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2
147
Tianjin
2026-09-30
Not yet open
Phase II Study of Trastuzumab Rezetecan Combined With Retlirafusp Alfa With or Without CAPOX as Perioperative Therapy for Resectable Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
NCT07802288Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2
80
Tianjin
2026-09-30
Not yet open
A Study on the Efficacy of Different Doses of Oryz-Aspergillus Enzyme And Pancreatin Tablet in Treating Pancreatic Exocrine Insufficiency After Gastrointestinal Surgery
NCT07751367Pancreatic Exocrine Insufficiency, Adul
Tianjin Medical University Cancer Institute and Hospital
Not applicable
150
Tianjin
2026-09-18
Recruiting
Efficacy and Safety of Stereotactic Body Radiation Therapy for Spinal Metastases With Bilsky Grade 1c-3
NCT07809672Stereotactic Body Radiation Therapy (SBRT), Spinal Metastases
Tianjin Medical University Cancer Institute and Hospital
Not applicable
50
Tianjin
2026-09-03
Recruiting
Iparomlimab/Tuvonralimab Plus SBRT and Lenvatinib for Perioperative Treatment of Potentially Resectable Intermediate-Stage HCC
NCT07801287HCC - Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2
20
Tianjin
2026-09-01
Recruiting
HDR Endorectal Brachytherapy With 3D-Printed Guidance and Local Shielding for Rectal Cancer Organ Preservation
NCT07786493Rectal Cancer, Adenocarcinoma
Tianjin Medical University Cancer Institute and Hospital
Not applicable
50
Tianjin
2026-09-01
Recruiting
Phase II Study of SHR-A1811 for Ultra-Low HER2 Advanced Breast Cancer
NCT07817082Advanced Breast Cancer With Ultra-Low HER2 Expression
Tianjin Medical University Cancer Institute and Hospital
Phase 2
30
Tianjin
2026-09-01
Not yet open
Thiotepa Administration Via Ommaya Reservoir for Leptomeningeal Metastases in Non-Small Cell Lung Cancer Resistant to EGFR-TKI.
NCT07778940Leptomeningeal Metastasis
Tianjin Medical University Cancer Institute and Hospital
Phase 2
50
Tianjin
2026-09
Not yet open
SBRT Combined With Reduced-Dose Anthracycline Chemotherapy and Toripalimab as Neoadjuvant Therapy for Localized High-Risk Undifferentiated Pleomorphic Sarcoma
NCT07817095Undifferentiated Pleomorphic Sarcoma (UPS)
Tianjin Medical University Cancer Institute and Hospital
Phase 2
39
Tianjin
2026-09
Not yet open
Baduanjin for Quality of Life in Pancreatic Cancer Chemotherapy
NCT07791550Pancreatic Neoplasms, Pancreatic Cancer, Drug-Related Side Effects and Adverse Reactions (MeSH Term)
Tianjin Medical University Cancer Institute and Hospital
Not applicable
96
Tianjin
2026-08-28
Not yet open
Five-Element Music Therapy for Psychological Distress in Pancreatic Cancer Chemotherapy
NCT07796906Pancreatic Neoplasms, Pancreatic Cancer, Anxiety, Depression and/or Anxiety Symptoms
Tianjin Medical University Cancer Institute and Hospital
Not applicable
320
Tianjin
2026-08-28
Not yet open
AK112 Combination Therapy as First Line Treatment for Metastatic Digestive System Neuroendocrine Cancer
NCT07712094Neuroendocrine Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2
56
Baotou, Tongliao, Taiyuan, Tianjin
2026-08-01
Not yet open
Multi-Cohort Study of Zeprumetostat Combinations for Relapsed/Refractory PTCL
NCT07724782PTCL-NOS
Tianjin Medical University Cancer Institute and Hospital
Phase 1/2
33
Tianjin
2026-08-01
Not yet open
A Phase II Exploratory Study of Sacituzumab Tirumotecan Combined With Envafolimab for TROP2-Positive Advanced Biliary Tract Cancers Previously Treated With First-Line Immunotherapy Combined With Chemotherapy.
NCT07729033Advanced Biliary Tract Cancers
Tianjin Medical University Cancer Institute and Hospital
Phase 2
28
Tianjin
2026-08
Not yet open
To Explore a Single-arm Phase II Study on Intestinal Microbiota Transplantation Combined With Neoadjuvant Immunotherapy and Chemoradiotherapy for Locally Advanced Rectal Cancer Under MSS/pMMR
NCT07738042Locally Advanced Rectal Cancer (LARC)
Tianjin Medical University Cancer Institute and Hospital
Not applicable
46
Tianjin
2026-07-31
Recruiting
Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCC
NCT07733830Esophageal Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2
120
Beijing, Zhengzhou, Shenyang, Taiyuan, Chengdu, Tianjin
2026-07-31
Recruiting
Hypofractionated Radiotherapy After Complete Resection for Stage II/III Thymic Epithelial Tumors
NCT07691619Thymic Epithelial Tumor
Tianjin Medical University Cancer Institute and Hospital
Phase 2
49
Tianjin
2026-07-14
Not yet open
Early Response-guided Sequential Radiotherapy After Chemoimmunotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
NCT07721103Esophageal Squamous Cell Carcinoma (ESCC)
Tianjin Medical University Cancer Institute and Hospital
Phase 2
110
Tianjin
2026-07-14
Not yet open
Phase II Trial of SFRT Plus Chemo-immunotherapy for LA-NSCLC With Suboptimal Neoadjuvant Response
NCT07670715Locally Advanced Non-small Cell Lung Cancer (NSCLC), Thoracic Radiotherapy, Immune Checkpoint Inhibitors, Neoadjuvant Chemoimmunotherapy
Tianjin Medical University Cancer Institute and Hospital
Phase 2
30
Tianjin
2026-07-01
Recruiting
Neoadjuvant EGFR-ADC Combined With Anti-PD-1 Monoclonal Antibody in Resectable Locally Advanced Hypopharyngeal Squamous Cell Carcinoma
NCT07665190Hypopharyngeal Squamous Cell Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2
52
Tianjin
2026-07-01
Not yet open
A Single-arm, Multi-center, Phase II Exploratory Clinical Study to Evaluate the Efficacy and Safety of Trilaciclib in Preventing Myelosuppression Caused by Topoisomerase I Inhibitor Type ADC Drugs
NCT07736001Tumor Patients
Tianjin Medical University Cancer Institute and Hospital
Not applicable
96
Tianjin
2026-07
Not yet open
Toripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist in the Perioperative Treatment of Resectable Non-small Cell Lung Cancer
NCT07358689NSCLC
Tianjin Medical University Cancer Institute and Hospital
Phase 2
120
Tianjin
2026-06-30
Not yet open
Serplulimab Plus Decitabine and CAPOX Before Surgery for Locally Advanced Colorectal Cancer
NCT07691632Locally Advanced Colorectal Cancer, Colorectal Adenocarcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2
35
Tianjin
2026-06-30
Recruiting
Fosrolapitant Combined With Palonosetron to Prevent Trastuzumab Rezetecan Related CINV
NCT07726433Chemotherapy-Induced Nausea and Vomiting (CINV)
Tianjin Medical University Cancer Institute and Hospital
Phase 2
56
Tianjin
2026-06-15
Active, closed
Eparlitozoviril as Adjuvant Therapy for Resectable HCC With MVI
NCT07658105HCC - Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2
60
Tianjin
2026-06-12
Not yet open
Exploratory Study of SHR-A1811 Via Different Administration Routes in Patients
NCT07560475HER2positive, Advanced Breast Cancer, HER2 + Breast Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2
60
Tianjin
2026-06-10
Recruiting
A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence
NCT07475026HCC - Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 3
198
Tianjin
2026-06-09
Not yet open
Clinical Study on the Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Nab-Paclitaxel in Neoadjuvant Therapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
NCT07493993ESCC
Tianjin Medical University Cancer Institute and Hospital
Phase 2
26
Tianjin
2026-06-01
Recruiting
Radiotherapy With GX Regimen as Adjuvant Therapy for High-risk Patients Following Pancreatic Cancer Surgery
NCT07632118Pancreatic Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 3
288
Tianjin
2026-05-22
Recruiting
IRE After Targeted Immunotherapy in HCC With Portal Vein Tumor Thrombus
NCT07799922IRE
Tianjin Medical University Cancer Institute and Hospital
Not applicable
60
Tianjin
2026-05-20
Recruiting
IRE After Chemotherapy for Locally Advanced Pancreatic Cancer
NCT07799935IRE
Tianjin Medical University Cancer Institute and Hospital
Not applicable
60
Tianjin
2026-05-20
Recruiting
Feasibility and Effectiveness of Respiratory Movement Management in Lung Cancer Receiving Stereotactic Radiotherapy Using a Novel Positional Fixation Device
NCT07561567Lung Cancer, Non-Small Cell
Tianjin Medical University Cancer Institute and Hospital
Observational
50
Tianjin
2026-05-10
Recruiting
Short-Course Radiotherapy Followed by Immunotherapy Combined With Chemotherapy for Microsatellite Stable Locally Advanced Rectal Cancer: A Prospective, Randomized, Controlled Phase II Clinical Trial
NCT07594925Rectal Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2
130
Tianjin
2026-05-01
Recruiting
Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure
NCT07528274NSCLC (Non-small Cell Lung Cancer), NSCLC (Advanced Non-small Cell Lung Cancer)
Tianjin Medical University Cancer Institute and Hospital
Phase 2
20
Tianjin
2026-05-01
Not yet open
A Phase II Study of Benmelstobart + Anlotinib + Chemotherapy as First-Line Treatment for LCNEC and EP-NEC
NCT07510594Large-Cell Neuroendocrine Carcinoma of the Lung, Extrapulmonary Neuroendocrine Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2
48
Tianjin
2026-05-01
Active, closed
Sintilimab Combined With Ipilimumab (N01) Plus AG as First-line Therapy for uBTC.
NCT07654530Biliary Tract Cancers (BTC)
Tianjin Medical University Cancer Institute and Hospital
Phase 2
107
Tianjin
2026-04-24
Not yet open
Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy
NCT07372079Breast Cancer, Neoadjuvant Therapy, Immune Checkpoint Inhibitors, QL1706
Tianjin Medical University Cancer Institute and Hospital
Phase 2
40
Tianjin
2026-04-05
Recruiting
Risk-Stratified Management of Inavolisib-Induced Hyperglycemia and Patient Adherence
NCT07817056Breast Cancer, Hyperglycemia
Tianjin Medical University Cancer Institute and Hospital
Observational
100
Tianjin
2026-04-01
Recruiting
HCCANANO-HOPE1: IRE After Chemotherapy for Locally Advanced Unresectable Perihilar Cholangiocarcinoma
NCT07795619IRE
Tianjin Medical University Cancer Institute and Hospital
Not applicable
60
Tianjin
2026-04-01
Not yet open
Iparomlimab and Tuvonralimab Injection Combined With SBRT in Patients With Early-Stage Non-Small Cell Lung Cancer
NCT07379398NSCLC
Tianjin Medical University Cancer Institute and Hospital
Phase 2
28
Tianjin
2026-04-01
Not yet open
Prospective, Open-label, Multi-cohort Study of Becotatug Vedotin With Tislelizumab and Chemotherapy in Esophageal Squamous Cell Carcinoma - Phase 2
NCT07531979ESCC, Tislelizumab, Chemotherapy, Becotatug Vedotin
Tianjin Medical University Cancer Institute and Hospital
Phase 2
93
Tianjin
2026-04-01
Recruiting
Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular Carcinoma
NCT07560488HCC - Hepatocellular Carcinoma, Conversion Therapy
Tianjin Medical University Cancer Institute and Hospital
Phase 2
43
Tianjin
2026-03-30
Recruiting
The Effect of Braun Anastomosis on Delayed Gastric Emptying (DGE) in Reconstruction After Pancreaticoduodenectomy
NCT07681128Periampullary Carcinoma Resectable
Tianjin Medical University Cancer Institute and Hospital
Not applicable
264
Tianjin
2026-03-30
Recruiting
Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC
NCT07457528Resectable Esophageal Squamous Cell Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2
46
Tianjin
2026-03-12
Recruiting
Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic Cancer
NCT07436741Pancreatic Cancer, Adult
Tianjin Medical University Cancer Institute and Hospital
Phase 3
106
Tianjin
2026-03-03
Recruiting
A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer
NCT07506109BRAF V600E, Colorectal Cancer, Sintilimab, MSS (Microsatellite Stable)
Tianjin Medical University Cancer Institute and Hospital
Phase 2
49
Beijing, Wuhan, Chengdu, Tianjin
2026-03-01
Active, closed
A Pan-Cancer Retrospective Study on the Relationship Between Tumor Microenvironment Composition and Efficacy of Antibody-Based Antitumor Therapy
NCT07584044Tumor Microenvironment, Antibody
Tianjin Medical University Cancer Institute and Hospital
Observational
300
Tianjin
2026-03-01
Active, closed
Efficacy and Safety of HAIC Combined With Lenvatinib and PD-1 Inhibitors for Advanced Intrahepatic Cholangiocarcinoma
NCT07646717Intrahepatic Cholangiocarcinoma (Icc)
Tianjin Medical University Cancer Institute and Hospital
Phase 2
30
Tianjin
2026-02-24
Recruiting
CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL
NCT07397832Diffuse Large B-Cell Lymphoma (DLBCL)
Tianjin Medical University Cancer Institute and Hospital
Phase 2
58
Tianjin
2026-02-03
Not yet open
Iparomlimab and Tuvonralimab Injection Combined With GemOX and Lenvatinib as Conversion Therapy for Initially Potentially Resectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer
NCT07263360BTC
Tianjin Medical University Cancer Institute and Hospital
Phase 2
29
Tianjin
2026-02-01
Recruiting
A Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy
NCT07548060NSCLC Stage IV, EGFR Gene Mutation
Tianjin Medical University Cancer Institute and Hospital
Phase 2
25
Tianjin
2026-02-01
Recruiting
A Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer
NCT07358676Small Cell Lung Cancer (SCLC), SCLC, Extensive Stage
Tianjin Medical University Cancer Institute and Hospital
Phase 2
25
Tianjin
2026-02-01
Recruiting
A Single-Arm Phase Ⅱ Study of Fluzoparib Maintenance in Platinum-sensitive Advanced Triple-Negative Breast Cance
NCT07321015Platinum-sensitive, TNBC, Triple Negative Breast Cancer, BRCA1/2 Mutation or Not
Tianjin Medical University Cancer Institute and Hospital
Phase 2
72
Tianjin
2026-01-20
Recruiting
Phase II Study of Chidamide-Dinutuximab Beta-Irinotecan-Temozolomide for Refractory/Relapsed Neuroblastoma in Children
NCT07318831Neuroblastoma (NB), Neuroblastoma in Children
Tianjin Medical University Cancer Institute and Hospital
Phase 2
27
Tianjin
2026-01-06
Recruiting
Hippocampus-Protective Radiotherapy Combined With Osimertinib for Symptomatic Brain Metastases in EGFR-Mutated Lung Cancer
NCT07505173Naive Advanced Non-small Cell Lung Cancer With EGFR-sensitive Mutations (EGFR Exon 19 Deletion and Exon 21 L858R Mutation) and Symptomatic Brain Metastases
Tianjin Medical University Cancer Institute and Hospital
Phase 2
74
Tianjin
2026-01-01
Recruiting
Development and Application of an AI Chatbot for Perioperative Health Education in Thyroid Cancer Patients
NCT07634978Thyroid Cancer
Tianjin Medical University Cancer Institute and Hospital
Not applicable
150
Tianjin
2026-01-01
Not yet open
Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study
NCT07365410Non-small Cell Lung Cancer (NSCLC), Brain Metastases, Furmonertinib, EGFR Mutation
Tianjin Medical University Cancer Institute and Hospital
Phase 2
60
Tianjin
2026-01
Not yet open
A Multicenter Real-World Study on TKI Therapy After Progression on First-Line TKI/IO Therapy or TKI/IO Therapy After Progression on First-Line TKI in Chinese Patients With Metastatic Renal Cell Carcinoma (mRCC)
NCT07324876RCC
Tianjin Medical University Cancer Institute and Hospital
Observational
860
Tianjin
2025-12-31
Recruiting
Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases
NCT07304739Non Small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2
30
Cangzhou, Tianjin
2025-12-22
Not yet open
Efficacy and Safety of Anrikefon Injection for the Treatment of Postoperative Pain in Patients Undergoing Totally Laparoscopic Radical Distal Gastrectomy
NCT07330063Gastrectomy
Tianjin Medical University Cancer Institute and Hospital
Phase 2
114
Tianjin
2025-12-22
Not yet open
Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer
NCT07246317Breast Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2
188
Guangzhou, Shijiazhuang, Luoyang, Nanyang, Chengdu, Tianjin, Jiaxing
2025-12-15
Active, closed
Prognostic Model of Elderly Hodgkin Lymphoma in China
NCT07374068Hodgkin Lymphoma
Tianjin Medical University Cancer Institute and Hospital
Observational
400
Tianjin
2025-12-09
Active, closed
A Clinical Study to Evaluate GK01 Cell Injection in Combination With PD-1 Monoclonal Antibody for Advanced Solid Tumors
NCT07407985Solid Tumors
Tianjin Medical University Cancer Institute and Hospital
Phase 1
15
Tianjin
2025-12-04
Recruiting
Serplulimab for Locally Advanced Cervical Cancer
NCT07340489Cervical Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2
216
Tianjin
2025-12-03
Recruiting
WAST Cell-Docetaxel Combination Therapy in PD-1 Inhibitor-Resistant Advanced NSCLC
NCT07330050NSCLC (Non-small Cell Lung Cancer)
Tianjin Medical University Cancer Institute and Hospital
Phase 2
31
Tianjin
2025-12-01
Recruiting
TALENT Study: Phase II Trial of Adjuvant L-TIL Plus Tislelizumab in Resectable NSCLC Without pCR After Neoadjuvant Chemoimmunotherapy
NCT07330037NSCLC
Tianjin Medical University Cancer Institute and Hospital
Phase 2
41
Tianjin
2025-12-01
Not yet open
Sac-TMT Plus Bevacizumab as Second-Line Treatment for Advanced Non-Squamous Non-Small Cell Lung Cancer
NCT07244926Lung Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2
31
Tianjin
2025-12
Recruiting
Specialist Nurse-Led Nursing Management for Patients Undergoing Head and Neck Cancer Surgery
NCT07622381Head & Neck Cancer
Tianjin Medical University Cancer Institute and Hospital
Not applicable
80
Tianjin
2025-11-24
Recruiting
DCRT vs. Surgery in Resectable ESCC Patient Achiving cCR/PR After nCI
NCT07162506Esophageal Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2
120
Tianjin
2025-11-03
Recruiting
Liposomal Irinotecan, Capecitabine and Enlonstobart With Short-Course Radiotherapy for Locally Advanced Rectal Cancer
NCT07281157Advanced Rectal Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2
30
Tianjin
2025-11-01
Not yet open
Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer
NCT07172412Extensive Stage Lung Small Cell Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2
165
Tianjin
2025-11
Recruiting
Surgical Total Clearance Versus Extrahepatic Bile Duct Preservation for Biliary Tract Malignancies: A Single-Center, Randomized, Two-Arm, Prospective Phase II Clinical Trial
NCT07609641BTC
Tianjin Medical University Cancer Institute and Hospital
Not applicable
60
Tianjin
2025-10-20
Recruiting
A Single-arm, Open-label Study of GK01 in Combination With or Without Chemotherapy for the Adjuvant Treatment of Solid Tumors
NCT07351903Solid Tumors
Tianjin Medical University Cancer Institute and Hospital
Phase 1
15
Tianjin
2025-10-16
Recruiting
Tislelizumab Combined With Chemotherapy for Different Cycles of Neoadjuvant Therapy for Locally Advanced Resectable Squamous Cell Carcinoma of the Head and Neck (NeoTempo)
NCT07147426Head &Amp; Neck Squamous Cell Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2
100
Tianjin
2025-10-01
Not yet open
Chemotherapy Combined With Targeted Therapy as First-line Treatment for Mantle Cell Lymphoma Based on MRD and PET-CT Assessment
NCT07206264Mantle Cell Lymphoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2
45
Fuzhou, Shijiazhuang, Harbin, Jinan, Tianjin
2025-10
Recruiting
FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma
NCT07012798Hepatocellular Carcinoma (HCC)
Tianjin Medical University Cancer Institute and Hospital
Phase 2
30
Tianjin
2025-09-25
Not yet open
Analysis of Deoxyribonucleic Acid and Ribonucleic Acid Next-Generation Sequencing in Non-Small Cell Lung Cancer Patients Without Pathological Complete Response Following Neoadjuvant Immunotherapy
NCT07179445NSCLC
Tianjin Medical University Cancer Institute and Hospital
Observational
300
Tianjin
2025-09-20
Not yet open
Gecacitinib Combined With Donafenib and PD-1 Inhibitor as Immune Rechallenge Therapy for Unresectable Hepatocellular Carcinoma
NCT07157306Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2
35
Tianjin
2025-09-10
Recruiting
Chemoradiation Plus Iparomlimab Consolidation in Older With ESCC
NCT07038629Esophageal Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2
52
Tianjin
2025-09-08
Not yet open
Sacituzumab Tirumotecan Plus Tagitanlimab in Previously Treated Locally Advanced or Metastatic Triple Negative Breast Cancer
NCT07153965Triple Negative Breast Cancer (TNBC), PD-L1 Positive
Tianjin Medical University Cancer Institute and Hospital
Phase 2
47
Tianjin
2025-09-01
Recruiting
An Exploratory Study on the Efficacy and Safety of Enlonstobart Combined With Concurrent Radiotherapy and Chemotherapy Following Induction Therapy With Enlonstobart Plus Chemotherapy in Patients With Locally Advanced Cervical Cancer.
NCT07776821Uterine Cervical Neoplasms
Tianjin Medical University Cancer Institute and Hospital
Phase 4
31
Tianjin
2025-09-01
Recruiting
Lparomlimab and Tuvonralimab Injection in Combination With TACE and Lenvatinib in the Treatment of Second-Line Therapy for Unresectable Intermediate-to-Advanced Hepatocellular Carcinoma
NCT07099274HCC
Tianjin Medical University Cancer Institute and Hospital
Phase 2
29
Tianjin
2025-08-22
Recruiting
The Possible Range of No.4sb Lymph Node Dissection of Locally Advanced Distal Gastric Cancer
NCT07183150Gastric Cancer (GC), No.4sb
Tianjin Medical University Cancer Institute and Hospital
Observational
400
Tianjin
2025-08-18
Not yet open
Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast Cancer
NCT07139470Triple Negative Breast Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 1/2
59
Tianjin
2025-08-15
Not yet open
RN1201 Injection in Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma
NCT07114432Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma Patients Ineligible or Unwilling to Undergo ASCT, Newly Diagnosed Multiple Myeloma (NDMM)
Tianjin Medical University Cancer Institute and Hospital
Phase 1
19
Tianjin
2025-08
By invitation
Impact of an Artificial Intelligence-Based Management Model on Psychological and Behavioral Outcomes in Breast Cancer Patients Undergoing Home CDK4/6 Inhibitor Therapy
NCT07409298CDK4/6 Inhibitors, Depression Anxiety Disorder, Breast Cancer
Tianjin Medical University Cancer Institute and Hospital
Not applicable
300
Tianjin
2025-07-05
Recruiting
Spatially Fractionated Radiotherapy Combined With Immunotherapy for Advanced Solid Tumors
NCT07058948Solid Cancers, Radiotherapy, Immune Checkpoint Inhibitor, Lung Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2
30
Beijing, Cangzhou, Tianjin
2025-07-01
Not yet open
BR Combined With OR in Treatment-naïve Marginal Zone Lymphoma
NCT07008053Marginal Zone Lymphomas
Tianjin Medical University Cancer Institute and Hospital
Phase 2
37
Fuzhou, Shijiazhuang, Changsha, Jinan, Qingdao, Tianjin
2025-07
Not yet open
Clinical Study of QL1706 in Combination With Olaparib for the Treatment of Patients With Previously Treated Homologous Recombination Repair-Deficient Recurrent or Metastatic Triple-Negative Breast Cancer
NCT07005583Triple-Negative Breast Cancer (TNBC)
Tianjin Medical University Cancer Institute and Hospital
Phase 2
46
Tianjin
2025-06-30
Recruiting
Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab Failure
NCT07708194Breast Cancer, HER2-positive Breast Cancer, Hormone Receptor-Positive Breast Cancer, Metastatic Breast Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 1/2
94
Tianjin
2025-06-23
Recruiting
Real-world Studies of CDK4/6 Inhibitors
NCT07407439Breast Cancer
Tianjin Medical University Cancer Institute and Hospital
Observational
245
Tianjin
2025-06-01
Recruiting
Postoperative Edge (RapidArc) Stereotactic Body Radiotherapy for Spinal Metastases
NCT07801274Spinal Metastases, Metastatic Epidural Spinal Cord Compression, Spinal Cord Compression
Tianjin Medical University Cancer Institute and Hospital
Observational
50
Tianjin
2025-06-01
Not yet open
Ivonescimab in Combination With Liposomal Irinotecan and 5-FU/LV in Potentially Resectable Biliary Tract Malignancies
NCT06993025Biliary Tract Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2
30
Tianjin
2025-05-25
Recruiting
QL1706-Based Therapy Post-PD-1/L1 Failure in Advanced Endometrial Cancer
NCT06917092Endometrial Adenocarcinoma, Endometrial Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2
30
Tianjin
2025-05-01
Recruiting
Cryoablation Combined With Tislelizumab and Chemotherapy as Neoadjuvant and Adjuvant Therapy in Resectable Stage II-IIIB NSCLC
NCT06939127NSCLC (Non-small Cell Lung Cancer)
Tianjin Medical University Cancer Institute and Hospital
Phase 2
38
Tianjin
2025-04-01
Recruiting
A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies
NCT06914037Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma (CTCL), NHL (Non-Hodgkin Lymphoma)
Tianjin Medical University Cancer Institute and Hospital
Phase 1
24
Tianjin
2025-03-31
Recruiting
A Study on Ivonescimab Plus Chemotherapy as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer
NCT06944106Pancreatic Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2
30
Tianjin
2025-03-28
Recruiting
A Single-Arm, Open-Label, Phase I Study of GK01 for Advanced Solid Tumor
NCT06954558Advanced Solid Tumors
Tianjin Medical University Cancer Institute and Hospital
Phase 1
15
Tianjin
2025-03-18
Recruiting
QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer
NCT06951997Metastatic Pancreatic Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2
33
Tianjin
2025-03-07
Rows per page Showing 1–100 of 170
1 2 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/tianjin

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 170 of those studies with a site in Tianjin that also match the filters currently applied.

How many clinical trials are recruiting in Tianjin?

106 of the 170 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 44 have not yet opened recruitment, 15 are active but closed to new participants, and 5 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Tianjin), 170 studies
PhaseStudiesRecruitingShare
Phase 2996258.2%
Not applicable321918.8%
Observational1498.2%
Phase 1965.3%
Phase 3754.1%
Phase 1/2633.5%
Phase 4221.2%
Phase 2/3100.6%

Most active sponsors

Lead sponsors with the most studies (Tianjin)
Lead sponsorStudiesRecruiting
Tianjin Medical University Cancer Institute and Hospital170106
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.